Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 18th Annual Healthcare Conference
The presentation will be webcast and may be accessed in the Event Calendarpage under Investors on the Exelixis website at http://www.exelixis.com.
Exelixis, Inc. is a development-stage biotechnology company dedicated tothe discovery and development of novel small molecule therapeutics for thetreatment of cancer and other serious diseases. The company is leveraging itsfully integrated drug discovery platform to fuel the growth of its developmentpipeline, which is primarily focused on cancer. Currently, Exelixis' broadproduct pipeline includes investigational compounds in phase 2 and phase 1clinical development for cancer and renal disease. Exelixis has establishedstrategic corporate alliances with major pharmaceutical and biotechnologycompanies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech,Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visitthe company's web site at http://www.exelixis.com.
SOURCE Exelixis, Inc.
You May Also Like